Pharmacology of GABAC receptors: responses to agonists and antagonists distinguish A- and B-subtypes of homomeric rho receptors expressed in Xenopus oocytes.
GABA(C) receptors, expressed predominantly in vertebrate retina, are thought to be formed mainly by GABA rho subunits. Five GABA rho subunits have been cloned from white perch retina, four of which form functional homooligomeric receptors when expressed in Xenopus oocytes. These rho subtypes, classified as rho1A, rho1B, rho2A and rho2B receptors based on amino acid sequence alignment, exhibit distinct temporal and pharmacological properties. To examine further the pharmacological properties associated with the various rho receptor subtypes, we investigated the effects of a selective GABA(C) receptor antagonist, TPMPA, on the GABA-mediated activity of receptors formed in Xenopus oocytes by the four GABA rho subunits. In addition, we recorded the activation profiles of beta-alanine, taurine, and glycine, three amino acids that modulate neuronal activity in various parts of the CNS and are purported to be rho receptor agonists. TPMPA effectively inhibited GABA-elicited responses on A-type receptors, whereas B-type receptors exhibited a relatively low sensitivity to the drug. A-type and B-type receptors also displayed distinctly different reactions to agonists. Both taurine and glycine-activated the B-type receptors, whereas these agents had no detectable effect on A-type receptors. Similarly, beta-alanine evoked large responses from B-type receptors, but was far less effective on A-type receptors. These results indicate that, in addition to the characteristic response properties identified previously, there is a pattern of pharmacological reactions that further distinguishes the A- and B-subtypes of GABA rho receptor.
Pan
Yi
Y
Department of Ophthalmology and Visual Sciences, University of Illinois College of Medicine, 1855 West Taylor Street, Chicago, IL 60612, USA.
Khalili
Parham
P
Ripps
Harris
H
Qian
Haohua
H
D000409:Alanine / Q000494:pharmacology; D000818:Animals; D004305:Dose-Response Relationship, Drug; D005260:Female; D018755:GABA Agonists / Q000494:pharmacology; D018756:GABA Antagonists / Q000494:pharmacology; D005998:Glycine / Q000494:pharmacology; D008564:Membrane Potentials / Q000187:drug effects; D008845:Microinjections / Q000379:methods; D009865:Oocytes / Q000187:drug effects / Q000378:metabolism*; D018408:Patch-Clamp Techniques / Q000379:methods; D010471:Perches; D010721:Phosphinic Acids / Q000494:pharmacology; D011487:Protein Conformation; D021122:Protein Subunits / Q000187:drug effects / Q000502:physiology*; D011725:Pyridines / Q000494:pharmacology; D018079:Receptors, GABA / Q000145:classification / Q000187:drug effects / Q000502:physiology*; D013654:Taurine / Q000494:pharmacology; D014982:Xenopus laevis / Q000378:metabolism*; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology
C101879:(1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid; D018755:GABA Agonists; D018756:GABA Antagonists; C087200:GABA-C receptor; D010721:Phosphinic Acids; D021122:Protein Subunits; D011725:Pyridines; D018079:Receptors, GABA; D013654:Taurine; D005680:gamma-Aminobutyric Acid; D000409:Alanine; D005998:Glycine